Sarepta Therapeutics surges 36% after FDA approval for expanded treatment options

From Investing.com: 2024-06-20 18:13:06

Sarepta Therapeutics surges in after-hours trading following FDA approval for ELEVIDYS, a drug for Duchenne muscular dystrophy in patients aged 4 and above with a specific gene mutation. Full approval provided for walking patients, conditional approval for non-walking patients pending further research. CEO and co-inventor show excitement for expanded treatment options. Study underway to confirm benefits for non-walking patients. Collaboration with Roche to bring ELEVIDYS globally.



Read more at Investing.com: Sarepta Therapeutics surges 36% after-hours following expanded FDA approval By Investing.com